<style>
.table-wrap{overflow:auto; max-width:100%;}
.segment-pivot { width:100%; border-collapse:collapse; font-family: Arial, sans-serif; font-size:14px; }
.segment-pivot thead th { position:sticky; top:0; background:#fff; z-index:1; border-bottom:1px solid #ddd; }
.segment-pivot th, .segment-pivot td { padding:6px 8px; border-bottom:1px solid #f0f0f0; }
.segment-pivot tbody tr:nth-child(even){ background:#fafafa; }
.segment-pivot td, .segment-pivot th { white-space:nowrap; }
.segment-pivot td { font-variant-numeric: tabular-nums; text-align:right; }
.segment-pivot td:first-child, .segment-pivot th:first-child { text-align:left; }
.table-note { font-size:12px; color:#666; margin:6px 0 8px; }
</style>
<div class="table-note">SEGMENTS v2025-09-09 · 2025-10-15 12:30 UTC — Values are shown in a single scale for this table: <b>$B</b>. TTM values are <b>bold</b>. “% of Total (TTM)” shows revenue mix.</div>
<div class='table-wrap'><table class="dataframe segment-pivot">
  <thead>
    <tr style="text-align: right;">
      <th>Segment</th>
      <th>2022 Rev ($B)</th>
      <th>2022 OI ($B)</th>
      <th>2023 Rev ($B)</th>
      <th>2023 OI ($B)</th>
      <th>2024 Rev ($B)</th>
      <th>2024 OI ($B)</th>
      <th>TTM Rev ($B)</th>
      <th>TTM OI ($B)</th>
      <th>% of Total (TTM)</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Product</td>
      <td>80.9B</td>
      <td>0.00B</td>
      <td>80.8B</td>
      <td>0.00B</td>
      <td>85.8B</td>
      <td>0.00B</td>
      <td><strong>86.6B</strong></td>
      <td><strong>0.00B</strong></td>
      <td>42.6%</td>
    </tr>
    <tr>
      <td>H I V Product Sales</td>
      <td>34.4B</td>
      <td>0.00B</td>
      <td>36.4B</td>
      <td>0.00B</td>
      <td>39.2B</td>
      <td>0.00B</td>
      <td><strong>41.1B</strong></td>
      <td><strong>0.00B</strong></td>
      <td>20.2%</td>
    </tr>
    <tr>
      <td>H I V Products Biktarvy</td>
      <td>20.8B</td>
      <td>0.00B</td>
      <td>23.7B</td>
      <td>0.00B</td>
      <td>26.8B</td>
      <td>0.00B</td>
      <td><strong>28.4B</strong></td>
      <td><strong>0.00B</strong></td>
      <td>14.0%</td>
    </tr>
    <tr>
      <td>Oncology Product</td>
      <td>4.28B</td>
      <td>0.00B</td>
      <td>5.86B</td>
      <td>0.00B</td>
      <td>6.58B</td>
      <td>0.00B</td>
      <td><strong>6.55B</strong></td>
      <td><strong>0.00B</strong></td>
      <td>3.2%</td>
    </tr>
    <tr>
      <td>Liver Disease</td>
      <td>5.60B</td>
      <td>0.00B</td>
      <td>5.57B</td>
      <td>0.00B</td>
      <td>6.04B</td>
      <td>0.00B</td>
      <td><strong>5.94B</strong></td>
      <td><strong>0.00B</strong></td>
      <td>2.9%</td>
    </tr>
    <tr>
      <td>H I V Products Descovy</td>
      <td>3.74B</td>
      <td>0.00B</td>
      <td>3.97B</td>
      <td>0.00B</td>
      <td>4.22B</td>
      <td>0.00B</td>
      <td><strong>5.22B</strong></td>
      <td><strong>0.00B</strong></td>
      <td>2.6%</td>
    </tr>
    <tr>
      <td>Cell Therapy Products Total Cell Therapy Product Sales</td>
      <td>2.92B</td>
      <td>0.00B</td>
      <td>3.74B</td>
      <td>0.00B</td>
      <td>3.95B</td>
      <td>0.00B</td>
      <td><strong>3.77B</strong></td>
      <td><strong>0.00B</strong></td>
      <td>1.9%</td>
    </tr>
    <tr>
      <td>H I V Products Genvoya</td>
      <td>4.81B</td>
      <td>0.00B</td>
      <td>4.12B</td>
      <td>0.00B</td>
      <td>3.52B</td>
      <td>0.00B</td>
      <td><strong>3.19B</strong></td>
      <td><strong>0.00B</strong></td>
      <td>1.6%</td>
    </tr>
    <tr>
      <td>Other Products Yescarta</td>
      <td>2.32B</td>
      <td>0.00B</td>
      <td>3.00B</td>
      <td>0.00B</td>
      <td>3.14B</td>
      <td>0.00B</td>
      <td><strong>3.07B</strong></td>
      <td><strong>0.00B</strong></td>
      <td>1.5%</td>
    </tr>
    <tr>
      <td>Trodelvy</td>
      <td>1.36B</td>
      <td>0.00B</td>
      <td>2.12B</td>
      <td>0.00B</td>
      <td>2.63B</td>
      <td>0.00B</td>
      <td><strong>2.78B</strong></td>
      <td><strong>0.00B</strong></td>
      <td>1.4%</td>
    </tr>
    <tr>
      <td>Veklury</td>
      <td>7.81B</td>
      <td>0.00B</td>
      <td>4.37B</td>
      <td>0.00B</td>
      <td>3.60B</td>
      <td>0.00B</td>
      <td><strong>2.72B</strong></td>
      <td><strong>0.00B</strong></td>
      <td>1.3%</td>
    </tr>
    <tr>
      <td>Liver Disease Products Sofosbuvir Velpatasvir</td>
      <td>3.06B</td>
      <td>0.00B</td>
      <td>3.07B</td>
      <td>0.00B</td>
      <td>3.19B</td>
      <td>0.00B</td>
      <td><strong>2.53B</strong></td>
      <td><strong>0.00B</strong></td>
      <td>1.2%</td>
    </tr>
    <tr>
      <td>H I V Products Odefsey</td>
      <td>2.94B</td>
      <td>0.00B</td>
      <td>2.70B</td>
      <td>0.00B</td>
      <td>2.58B</td>
      <td>0.00B</td>
      <td><strong>2.45B</strong></td>
      <td><strong>0.00B</strong></td>
      <td>1.2%</td>
    </tr>
    <tr>
      <td>Liver Disease Products Vemlidy</td>
      <td>1.69B</td>
      <td>0.00B</td>
      <td>1.72B</td>
      <td>0.00B</td>
      <td>1.92B</td>
      <td>0.00B</td>
      <td><strong>2.01B</strong></td>
      <td><strong>0.00B</strong></td>
      <td>1.0%</td>
    </tr>
    <tr>
      <td>Other Products Total Other Product Sales</td>
      <td>1.89B</td>
      <td>0.00B</td>
      <td>1.72B</td>
      <td>0.00B</td>
      <td>1.78B</td>
      <td>0.00B</td>
      <td><strong>1.44B</strong></td>
      <td><strong>0.00B</strong></td>
      <td>0.7%</td>
    </tr>
    <tr>
      <td>Liver Disease Products Other Liver Disease</td>
      <td>0.85B</td>
      <td>0.00B</td>
      <td>0.77B</td>
      <td>0.00B</td>
      <td>0.93B</td>
      <td>0.00B</td>
      <td><strong>1.39B</strong></td>
      <td><strong>0.00B</strong></td>
      <td>0.7%</td>
    </tr>
    <tr>
      <td>Other Products Am Bisome</td>
      <td>0.99B</td>
      <td>0.00B</td>
      <td>0.98B</td>
      <td>0.00B</td>
      <td>1.06B</td>
      <td>0.00B</td>
      <td><strong>0.97B</strong></td>
      <td><strong>0.00B</strong></td>
      <td>0.5%</td>
    </tr>
    <tr>
      <td>H I V Products Symtuza Revenue Share</td>
      <td>1.06B</td>
      <td>0.00B</td>
      <td>1.06B</td>
      <td>0.00B</td>
      <td>1.18B</td>
      <td>0.00B</td>
      <td><strong>0.95B</strong></td>
      <td><strong>0.00B</strong></td>
      <td>0.5%</td>
    </tr>
    <tr>
      <td>H I V Products Other H I V</td>
      <td>1.06B</td>
      <td>0.00B</td>
      <td>0.80B</td>
      <td>0.00B</td>
      <td>0.87B</td>
      <td>0.00B</td>
      <td><strong>0.82B</strong></td>
      <td><strong>0.00B</strong></td>
      <td>0.4%</td>
    </tr>
    <tr>
      <td>Cell Therapy Products Tecartus</td>
      <td>0.60B</td>
      <td>0.00B</td>
      <td>0.74B</td>
      <td>0.00B</td>
      <td>0.81B</td>
      <td>0.00B</td>
      <td><strong>0.70B</strong></td>
      <td><strong>0.00B</strong></td>
      <td>0.3%</td>
    </tr>
    <tr>
      <td>Other Products Other</td>
      <td>0.90B</td>
      <td>0.00B</td>
      <td>0.73B</td>
      <td>0.00B</td>
      <td>0.71B</td>
      <td>0.00B</td>
      <td><strong>0.47B</strong></td>
      <td><strong>0.00B</strong></td>
      <td>0.2%</td>
    </tr>
    <tr>
      <td>Royalty Contract And Other</td>
      <td>0.90B</td>
      <td>0.00B</td>
      <td>0.55B</td>
      <td>0.00B</td>
      <td>0.43B</td>
      <td>0.00B</td>
      <td><strong>0.39B</strong></td>
      <td><strong>0.00B</strong></td>
      <td>0.2%</td>
    </tr>
  </tbody>
</table></div>